Society for Clinical Vascular Surgery
December 17, 2007

Salvage of Infected Vascular Grafts with Antibiotic Impregnated Beads

Back to Annual Symposium
Back to Program
Michael J. Klebuc, MD1, Hector Salazar, MD1, Eric Peden, MD2.
1Institute for Reconstructive Surgery, Houston, TX, USA, 2The Methodist Hospital Department of Vascular Surgery, Houston, TX, USA.

OBJECTIVES: To determine if antibiotic impregnated polymethylmethacrylate beads utilized in conjunction with serial debridement and local muscle flaps can enhance the salvage of infected vascular grafts.
METHODS: A retrospective review of 20 vascular graft infections treated in 19 patients over a 3 year period. The treatment protocol included serial debridement, placement of antibiotic beads (one 40 gram package polymethylmethacrylate + 4 grams powdered vancomycin + 2.4 grams powdered tobramycin) and culture specific intravenous antibiotics. Repeat debridement and bead exchange was performed every 3 to 5 days until a clean, culture negative wound was achieved. Formal closure was achieved with a local muscle flap followed by six weeks of intravenous antibiotics.
RESULTS: Twenty graft infections were treated in 19 patients with a mean age of 59 years of which 16 were acute and 4 sub-acute. Seventy percent of the grafts were alloplastic (Gortex, PTFE) and 30% autologous vein. The most commonly identified organisms were Enteroccus, Methycilin Sensitive Staphylococcus Aureus, Enterobacter Cloaccae and Methycilin Resistant Staphylococcus Aureus. On average 2.65 (±0.58) bead exchanges were performed over a mean treatment period of 9.05 (±5.24) days. After obtaining a clean, culture negative wound definitive coverage was provided with a local muscle flap. Successful graft salvaged was achieved in 95 % of patients and no patients (0%) required amputation. One recurrent infection (5%) was encountered requiring graft removal.
CONCLUSIONS: Polymethylmethacrylate antibiotic (PMMA) impregnated beads can provide a useful adjunct in the treatment of infected vascular bypass grafts. The 95% graft salvage and 0% limb loss rates compare favorably to historic controls (graft salvage 66%, amputation 12%).


Back to Annual Symposium
Back to Program